☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

Aspirin in diabetes

The British Medical Journal has published a paper that has concluded that aspirin is ineffective in preventing primary cardiovascular events in some patients with diabetes. This study has been reported in the media (BBC).

The study particularly looked at patients with diabetes and asymptomatic peripheral arterial disease (defined as a ankle brachial pressure index of 0.99 or less). These patients were randomised to one of four treatment groups including treatment with aspirin, antioxidants or matching placebo. The primary outcome for the study was a composite including death from coronary heart disease or stroke, non-fatal myocardial infarction or stroke.

The study recruited almost 1,300 patients with approximately 300 in each treatment group and ran for 8 years. The study found no difference in the primary endpoint for either treatment. The paper notes that, "small effects may be shown with larger trials continued for a longer time".

It should be noted that by year 6 of the study one third of patients had died but that deaths from vascular causes comprised less than half of these deaths. The authors of the study propose that optimal use of statins (mean cholesterol in patients with diabetes has dropped from 6.0 mmol/l in 1996 to 4.3 mmol/l in 2007) may be one explanation for lack of efficacy of aspirin in this study. Additionally, primary prevention studies have generally added statins to standard therapy with aspirin; this study raises the question whether aspirin is still necessary if statins are used.

Action: In the secondary prevention of cardiovascular disease aspirin therapy is effective and remains part of standard care. The place of aspirin in primary prevention of cardiovascular disease is questioned by this study but more work is required to confirm these findings before changes to practice are implemented.

Share 'Aspirin in diabetes' by emailShare 'Aspirin in diabetes' on FacebookShare 'Aspirin in diabetes' on TwitterShare 'Aspirin in diabetes' on LinkedInShare 'Aspirin in diabetes' on reddit


2 Comments to “Aspirin in diabetes”

  1. [...] The Lancet has published the results of a meta-analysis that aimed to assess the benefits and risks of aspirin therapy in the primary prevention of vascular events. This study has been reported in the general media (BBC) and builds on previous analyses. [...]

    Pingback by Prescribing Advice for GPs » Aspirin for primary prevention? — May 29, 2009 #

  2. I have being following you for a whiel, and wanted to congratuled you for all this great job you are doing! I am also a pharmaceutic, in the Canary Island, and today, you just made a huge diferent, because all the media is talking about the results, but you are the only one, talking about them and the variation of their cholestrol level, what could explain those results...

    Comment by ovidiov — October 18, 2008 #

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.